REZI:NYSEResideo Technologies, Inc. Analysis
Data as of 2026-07-03 - not real-time
$30.66
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Resideo Technologies (REZI) is trading around $30.66, well below its 20‑day SMA (~$31.07) and 50‑day SMA (~$33.33), signaling short‑term bearish pressure, yet the MACD histogram (+0.11) and a bullish MACD crossover suggest emerging upside. The forward P/E of ~10.2 is dramatically lower than the industry average of ~31.9, and the price‑to‑sales ratio of ~0.61 further underscores a valuation discount. Recent Q1 results showed a rebound to a modest net profit of $38 million on $1.912 billion revenue, reaffirming FY‑2026 revenue guidance of $7.8‑$7.9 billion, which has reignited investor interest. A pending spin‑off of the ADI Global Distribution segment could unlock additional value, but the company carries a high debt‑to‑equity ratio (>120) and negative free cash flow, keeping risk elevated.
Overall, the stock appears undervalued with upside potential if the spin‑off proceeds smoothly and margin improvements materialize, though volatility and leverage remain key concerns.
Overall, the stock appears undervalued with upside potential if the spin‑off proceeds smoothly and margin improvements materialize, though volatility and leverage remain key concerns.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below short‑term moving averages indicating bearish bias
- Bullish MACD histogram suggesting possible reversal
- Support level near $29.45 providing downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation discount vs industry (forward P/E ~10 vs 32)
- Reaffirmed FY‑2026 revenue guidance and recent profit turnaround
- Upcoming ADI Global Distribution spin‑off expected to improve balance sheet
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- High leverage (debt‑to‑equity >120) and modest free cash flow
- Transformation initiatives aimed at margin expansion
- Exposure to industrial distribution cycles and macro‑economic volatility
Key Metrics & Analysis
Financial Health
Revenue Growth8.00%
Profit Margin-6.50%
P/E Ratio10.2
ROE-15.79%
ROA5.06%
Debt/Equity120.33
P/B Ratio1.9
Op. Cash Flow$-1216999936
Free Cash Flow$127.8M
Industry P/E31.9
Technical Analysis
TrendBearish
RSI46.1
Support$29.45
Resistance$33.20
MA 20$31.07
MA 50$33.33
MA 200$35.98
MACDBullish
VolumeIncreasing
Fear & Greed Index92.98
Valuation
Target Price$51.00
Upside/Downside66.34%
GradeUndervalued
TypeBlend
Risk Assessment
Beta2.09
Volatility50.51%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.